http://orcid.org/0000-0002-9854-9063
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kasim Qureshi, Muhammad U. Farooq & Philip B. Gorelick. (2023) Genotype-guided dual antiplatelet therapy in cerebrovascular disease: assessing the risk and benefits for ethnic populations. Expert Review of Cardiovascular Therapy 21:9, pages 621-630.
Read now
Read now
Jathinder Kumar, Cormac T O’Connor, Rajesh Kumar, Samer Khalil Arnous & Thomas J. Kiernan. (2019) Coronary no-reflow in the modern era: a review of advances in diagnostic techniques and contemporary management. Expert Review of Cardiovascular Therapy 17:8, pages 605-623.
Read now
Read now
Articles from other publishers (19)
Gonzalo Villapalos-García, Pablo Zubiaur, Dolores Ochoa, Paula Soria-Chacartegui, Marcos Navares-Gómez, Miriam Matas, Gina Mejía-Abril, Ana Casajús-Rey, Diana Campodónico, Manuel Román, Samuel Martín-Vílchez, Carmen Candau-Ramos, Marina Aldama-Martín & Francisco Abad-Santos. (2023) NAT2 phenotype alters pharmacokinetics of rivaroxaban in healthy volunteers. Biomedicine & Pharmacotherapy 165, pages 115058.
Crossref
Crossref
E. V. Gantsgorn, A. V. Safronenko, E. V. Gubin, V. A. Vlasenko, E. V. Rashkova, I. M. Malleev, A. V. Ivanov, S. S. Gerasyuta, G. A. Bulguryan, Ya. O. Osipenko, O. V. Denisenko, D. A. Saakyan & M. H. Ivanova. (2023) Current Issues of the Use and Efficacy of Direct Oral Anticoagulants According their Pharmacogenetic Features. Journal Biomed 19:2, pages 37-44.
Crossref
Crossref
Xiaoyan Nie, Xinyi Zhang & Christine Y. Lu. 2020. Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy. Encyclopedia of Evidence in Pharmaceutical Public Health and Health Services Research in Pharmacy
1
49
.
Dan Zhang, Wei Qin, Wenwen Du, Xiaoxing Wang, Wenqian Chen & Pengmei Li. (2022)
Effect of
ABCB1
gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non‐valvular atrial fibrillation
. Biopharmaceutics & Drug Disposition 43:4, pages 163-171.
Crossref
Crossref
Georges Jourdi, Anne Godier, Marie Lordkipanidzé, Guillaume Marquis-Gravel & Pascale Gaussem. (2022) Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
AliMohammed Abd Alridha, KarrarMohammed Al-Gburi & SarahKadhim Abbood. (2022) A review of pharmacogenetics of anticoagulant therapy: Heparins, rivaroxaban, apixaban, and dabigatran. Medical Journal of Babylon 19:3, pages 332.
Crossref
Crossref
Natalia Shnayder, Marina Petrova, Elena Bochanova, Olga Zimnitskaya, Alina Savinova, Elena Pozhilenkova & Regina Nasyrova. 2021. Pharmacogenetics. Pharmacogenetics.
Natalia A. Shnayder, Marina M. Petrova, Pavel A. Shesternya, Alina V. Savinova, Elena N. Bochanova, Olga V. Zimnitskaya, Elena A. Pozhilenkova & Regina F. Nasyrova. (2021) Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines 9:5, pages 451.
Crossref
Crossref
Shengyu Zhang, Lingli Li, Mingying Deng, Yanan Wang, AiZong Shen & Lei Zhang. (2021) Di'ao Xinxuekang: Therapeutic Potential in Cardiovascular Diseases. Current Molecular Pharmacology 14.
Crossref
Crossref
Johanna Raymond, Laurent Imbert, Thibault Cousin, Thomas Duflot, Rémi Varin, Julien Wils & Fabien Lamoureux. (2021) Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. Journal of Personalized Medicine 11:1, pages 37.
Crossref
Crossref
Maria Grazia Perrone, Morena Miciaccia, Paola Vitale, Savina Ferorelli, Cristina da Costa Bernardes Araújo, Gabriella Silva de Almeida, Thaisa Francielle Souza Domingos, Luiz Claudio Rodrigues Pereira da Silva, Marcelo de Pádula, Lucio Mendes Cabral, Plínio Cunha Sathler, Carmela Bonaccorso, Cosimo G. Fortuna & Antonio Scilimati. (2021) An attempt to chemically state the cross-talk between monomers of COX homodimers by double/hybrid inhibitors mofezolac-spacer-mofezolac and mofezolac-spacer-arachidonic acid. European Journal of Medicinal Chemistry 209, pages 112919.
Crossref
Crossref
A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova & R. F. Nasyrova. (2020) Pharmacokinetics and Pharmacogenetics of Apixaban. Rational Pharmacotherapy in Cardiology 16:5, pages 852-860.
Crossref
Crossref
Adela-Nicoleta Roşian, Mihaela Iancu, Adrian Pavel Trifa, Ştefan Horia Roşian, Cristina Mada, Cornelia Paula Gocan, Teodora Niţă, Sabina Istratoaie, Paul-Mihai Boarescu & Anca Dana Buzoianu. (2020) An Exploratory Association Analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban. Journal of Personalized Medicine 10:3, pages 133.
Crossref
Crossref
A I Skripka, V V Kogay, A I Listratov, A A Sokolova, D A Napalkov & V V Fomin. (2019) Personalized approach for direct oral anticoagulant prescription: from theory to practice. Terapevticheskii arkhiv 91:7, pages 111-120.
Crossref
Crossref
Eberhard Wieland & Maria Shipkova. (2019) Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. Therapeutic Drug Monitoring 41:2, pages 180-191.
Crossref
Crossref
Troy J. Smith, Jessica L. Johnson, Abiy Habtewold & Melissa A. Burmeister. (2019) Cardiovascular Risk Reduction. Critical Care Nursing Clinics of North America 31:1, pages 15-30.
Crossref
Crossref
Barry S. Coller. 2019. Platelets. Platelets
xv
xxxviii
.
Ekaterina S. Kropacheva. (2018) PHARMACOGENETICS OF ANTITHROMBOTIC DRUGS: STATUS UPDATE ON THE PROBLEM. Atherothrombosis Journal:2, pages 115-129.
Crossref
Crossref
Adna Ašić, Damir Marjanović, Jure Mirat & Dragan Primorac. (2018) Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. Personalized Medicine 15:3, pages 209-221.
Crossref
Crossref